<DOC>
	<DOC>NCT00930163</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled study to evaluate the effects of lebrikizumab in patients with asthma who remain inadequately controlled while on chronic therapy with inhaled corticosteroids (ICS).</brief_summary>
	<brief_title>A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Body weight 40 kg150 kg Chest radiograph with no evidence of clinically significant abnormality Uncontrolled asthma Asthma exacerbation during screening Known malignancy Known immunodeficiency Preexisting lung disease other than asthma Uncontrolled clinically significant medical disease Current smoker History of substance abuse that may impair or risk the patient's full participation in the study, in the judgment of the investigator Prior allergic reaction to a monoclonal antibody Patients (men and women) of reproductive potential who are not willing to use contraception Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Adult Asthma</keyword>
</DOC>